Concepedia

Shah‐Jalal Sarker

SS

28

Publications

1.6K

Citations

20

H-Index

2007

Active since

Affiliations

Queen Mary University of London(Current)

University College London

Barts Health NHS Trust

St Bartholomew's Hospital

Nottingham University Hospitals NHS Trust

Shah‐Jalal Sarker is an author at Queen Mary University of London specializing in oncology, medicine, and radiation oncology.

ORCID

Top concepts

Publications per year

2007–2022

28

Publications

28

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Peter Schmid, Jacinta Abraham, Stephen Chan et al. · Journal of Clinical Oncology · 2019 · 373 citations · Full text

A Randomized Prospective Study Comparing Acquisition of Laparoscopic Skills in Three‐Dimensional (3D) vs. Two‐Dimensional (2D) Laparoscopy

B. Alaraimi, W. El Bakbak, Shah‐Jalal Sarker et al. · World Journal of Surgery · 2014 · 123 citations

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Thomas Powles, Matthew Wheater, Omar Din et al. · European Urology · 2015 · 97 citations

, , +5

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles, Alejo Rodríguez‐Vida, Ignacio Durán et al. · Journal of Clinical Oncology · 2018 · 90 citations

, , +15

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

Peter Schmid, Catherine Harper‐Wynne, M. Ferreira et al. · JAMA Oncology · 2019 · 90 citations · Full text

Rows per page

1–5 of 28